5:53 PM
 | 
Jun 07, 2017
 |  BC Innovations  |  Emerging Company Profile

Killer expansion

How CytoSen is using nanoparticles to expand NK cells

CytoSen Therapeutics Inc.'s nanoparticle technology expands and activates patient-derived NK cells ex vivo with fewer safety risks and manufacturing challenges than other expansion protocols.

Unlike T cells, which mount highly specific immune responses to pathogens or cancer cells, NK cells are components of the innate immune system that recognize and destroy any abnormal cell. That gives them potential against any type of cancer, in contrast to T cells, which have yet to show results beyond hematological malignancies.

But according to CytoSen president and co-founder Robert Igarashi, the broad potential of NK cells has not yet been realized because of difficult CMC. “The challenge the entire field has been facing for the past decade is producing a high enough dose,” Igarashi told BioCentury.

Most methods for expanding NK cells rely on co-culture with feeder cells, which...

Read the full 667 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >